Oncology Immunotherapy - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510241552

Publication Date:

October 1, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The global market for Oncology Immunotherapy was estimated to be worth US$ 2251 million in 2023 and is forecast to a readjusted size of US$ 3807.5 million by 2030 with a CAGR of 8.3% during the forecast period 2024-2030
The Oncology Immunotherapy market has expanded as a groundbreaking approach to treating cancer by harnessing the body's immune system to target and fight cancer cells. This innovative therapy includes immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, among others. By enhancing the immune response against tumors, immunotherapy offers potentially durable and targeted treatments, often with fewer side effects compared to traditional approaches. The market's growth is driven by promising clinical outcomes and a growing understanding of immune-tumor interactions. As researchers continue to explore and refine immunotherapeutic strategies, the Oncology Immunotherapy market remains at the forefront of oncology, revolutionizing cancer treatment paradigms and offering new hope to patients.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncology Immunotherapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oncology Immunotherapy by region & country, by Type, and by Application.
The Oncology Immunotherapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Immunotherapy.
麻豆原创 Segmentation
By Company
Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type:
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oncology Immunotherapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Oncology Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Oncology Immunotherapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Oncology Immunotherapy Product Introduction
1.2 Global Oncology Immunotherapy 麻豆原创 Size Forecast
1.3 Oncology Immunotherapy 麻豆原创 Trends & Drivers
1.3.1 Oncology Immunotherapy Industry Trends
1.3.2 Oncology Immunotherapy 麻豆原创 Drivers & Opportunity
1.3.3 Oncology Immunotherapy 麻豆原创 Challenges
1.3.4 Oncology Immunotherapy 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Oncology Immunotherapy Players Revenue Ranking (2023)
2.2 Global Oncology Immunotherapy Revenue by Company (2019-2024)
2.3 Key Companies Oncology Immunotherapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Oncology Immunotherapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Oncology Immunotherapy
2.6 Oncology Immunotherapy 麻豆原创 Competitive Analysis
2.6.1 Oncology Immunotherapy 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Oncology Immunotherapy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immunotherapy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immune Checkpoint Inhibitors
3.1.2 Cytokine-Based Immunotherapy
3.1.3 Cancer Vaccines
3.1.4 CAR-T Cell Therapy
3.1.5 Other
3.2 Global Oncology Immunotherapy Sales Value by Type
3.2.1 Global Oncology Immunotherapy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Oncology Immunotherapy Sales Value, by Type (2019-2030)
3.2.3 Global Oncology Immunotherapy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Drugstores
4.1.3 Others
4.2 Global Oncology Immunotherapy Sales Value by Application
4.2.1 Global Oncology Immunotherapy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Oncology Immunotherapy Sales Value, by Application (2019-2030)
4.2.3 Global Oncology Immunotherapy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Oncology Immunotherapy Sales Value by Region
5.1.1 Global Oncology Immunotherapy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Oncology Immunotherapy Sales Value by Region (2019-2024)
5.1.3 Global Oncology Immunotherapy Sales Value by Region (2025-2030)
5.1.4 Global Oncology Immunotherapy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Oncology Immunotherapy Sales Value, 2019-2030
5.2.2 North America Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Oncology Immunotherapy Sales Value, 2019-2030
5.3.2 Europe Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Oncology Immunotherapy Sales Value, 2019-2030
5.4.2 Asia Pacific Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Oncology Immunotherapy Sales Value, 2019-2030
5.5.2 South America Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Oncology Immunotherapy Sales Value, 2019-2030
5.6.2 Middle East & Africa Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Oncology Immunotherapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Oncology Immunotherapy Sales Value
6.3 United States
6.3.1 United States Oncology Immunotherapy Sales Value, 2019-2030
6.3.2 United States Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Oncology Immunotherapy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oncology Immunotherapy Sales Value, 2019-2030
6.4.2 Europe Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Oncology Immunotherapy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Oncology Immunotherapy Sales Value, 2019-2030
6.5.2 China Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
6.5.3 China Oncology Immunotherapy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Oncology Immunotherapy Sales Value, 2019-2030
6.6.2 Japan Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Oncology Immunotherapy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Oncology Immunotherapy Sales Value, 2019-2030
6.7.2 South Korea Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Oncology Immunotherapy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Oncology Immunotherapy Sales Value, 2019-2030
6.8.2 Southeast Asia Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Oncology Immunotherapy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Oncology Immunotherapy Sales Value, 2019-2030
6.9.2 India Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
6.9.3 India Oncology Immunotherapy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Profile
7.1.2 Bristol-Myers Squibb Main Business
7.1.3 Bristol-Myers Squibb Oncology Immunotherapy Products, Services and Solutions
7.1.4 Bristol-Myers Squibb Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.1.5 Bristol-Myers Squibb Recent Developments
7.2 Merck & Co
7.2.1 Merck & Co Profile
7.2.2 Merck & Co Main Business
7.2.3 Merck & Co Oncology Immunotherapy Products, Services and Solutions
7.2.4 Merck & Co Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.2.5 Merck & Co Recent Developments
7.3 Roche AG
7.3.1 Roche AG Profile
7.3.2 Roche AG Main Business
7.3.3 Roche AG Oncology Immunotherapy Products, Services and Solutions
7.3.4 Roche AG Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.3.5 AstraZeneca Recent Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Profile
7.4.2 AstraZeneca Main Business
7.4.3 AstraZeneca Oncology Immunotherapy Products, Services and Solutions
7.4.4 AstraZeneca Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.4.5 AstraZeneca Recent Developments
7.5 Sanofi S.A.
7.5.1 Sanofi S.A. Profile
7.5.2 Sanofi S.A. Main Business
7.5.3 Sanofi S.A. Oncology Immunotherapy Products, Services and Solutions
7.5.4 Sanofi S.A. Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi S.A. Recent Developments
7.6 Dendreon Pharmaceuticals
7.6.1 Dendreon Pharmaceuticals Profile
7.6.2 Dendreon Pharmaceuticals Main Business
7.6.3 Dendreon Pharmaceuticals Oncology Immunotherapy Products, Services and Solutions
7.6.4 Dendreon Pharmaceuticals Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.6.5 Dendreon Pharmaceuticals Recent Developments
7.7 Novartis
7.7.1 Novartis Profile
7.7.2 Novartis Main Business
7.7.3 Novartis Oncology Immunotherapy Products, Services and Solutions
7.7.4 Novartis Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.7.5 Novartis Recent Developments
7.8 Gilead Sciences Inc.
7.8.1 Gilead Sciences Inc. Profile
7.8.2 Gilead Sciences Inc. Main Business
7.8.3 Gilead Sciences Inc. Oncology Immunotherapy Products, Services and Solutions
7.8.4 Gilead Sciences Inc. Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.8.5 Gilead Sciences Inc. Recent Developments
7.9 Merck KGaA
7.9.1 Merck KGaA Profile
7.9.2 Merck KGaA Main Business
7.9.3 Merck KGaA Oncology Immunotherapy Products, Services and Solutions
7.9.4 Merck KGaA Oncology Immunotherapy Revenue (US$ Million) & (2019-2024)
7.9.5 Merck KGaA Recent Developments
8 Industry Chain Analysis
8.1 Oncology Immunotherapy Industrial Chain
8.2 Oncology Immunotherapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Oncology Immunotherapy Sales Model
8.5.2 Sales Channel
8.5.3 Oncology Immunotherapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.